Metabolic Syndrome and Related Disorders is an esteemed journal published by MARY ANN LIEBERT, INC, focusing on the multifaceted aspects of metabolic syndrome, including its interaction with chronic diseases such as diabetes, cardiovascular conditions, and obesity. Since its inception in 2003, this journal has established itself as a vital resource for researchers, healthcare professionals, and students dedicated to advancing knowledge in the fields of endocrinology, internal medicine, and metabolic disorders. With an impact factor reflective of its academic significance, Metabolic Syndrome and Related Disorders is recognized within the Q2 and Q3 quartiles in its respective categories, solidifying its reputation among scientific and clinical communities. Although it does not currently offer open access options, the journal remains committed to disseminating high-quality research and reviews that foster innovative solutions and improve patient outcomes. The journal's gradual convergence towards 2024 presents an exciting opportunity for continued exploration and dialogue about metabolic-related health challenges.

DIABETES OBESITY & METABOLISM, published by Wiley, is a premier international journal dedicated to the fields of endocrinology, diabetes, and metabolic disorders. With an impressive impact factor and its status as a Q1 journal in multiple categories—including Endocrinology and Internal Medicine—this publication is highly regarded in the academic community. Since its inception in 1999, the journal has served as a crucial platform for the dissemination of cutting-edge research, reviews, and clinical studies, driving advancements in understanding and treatment of diabetes and obesity. Researchers and professionals alike benefit from its rigorous peer-review process and extensive reach, as it aims to bridge the gap between laboratory findings and clinical applications. Although not an Open Access journal, articles are accessible through institutional subscriptions, ensuring that vital knowledge reaches those committed to enhancing patient care and expanding the scientific body of work in these pivotal areas.

Clinical and Experimental Hypertension, published by Taylor & Francis Inc, is a crucial resource in the fields of internal medicine and physiology. With its inaugural publication dating back to 1978, this esteemed journal has successfully merged decades of research, providing a platform for the latest advancements in hypertension studies. Operating without an open access model, it is configured to serve a specialized audience of researchers, clinicians, and students who are dedicated to exploring innovative treatment modalities and understanding the complexities of hypertensive diseases. Ranked in the Q3 category in both Internal Medicine and Physiology, this journal accomplishes a commendable standing in the academic community, exemplified by its Scopus rankings which position it within the median percentile range in its field. By disseminating high-quality research and fostering scientific dialogue, Clinical and Experimental Hypertension plays a pivotal role in shaping contemporary understanding and clinical practices concerning hypertension management.

CLINICAL SCIENCE, published by PORTLAND PRESS LTD, is a prestigious journal with an established history that dates back to 1946. Renowned for its rigorous peer-reviewed articles, the journal is dedicated to advancing knowledge in the field of medicine, particularly in the nuances of clinical science and translational research. With an impressive Q1 ranking in the **Medicine (miscellaneous)** category and a Scopus rank of #32 out of 636 in general medicine, it is firmly positioned in the top 5% percentile of its field, making it an essential resource for researchers, practitioners, and students aiming to stay at the forefront of the discipline. Although the journal operates on a traditional subscription model, its influence and accessibility ensure that critical findings and innovative methodologies reach a wide audience, fostering collaboration and progress within the global medical community. The journal seeks to publish groundbreaking studies, critical reviews, and insights that can translate into improved clinical practices, thus reinforcing its mission to enhance patient care and medical knowledge.

METABOLISM-CLINICAL AND EXPERIMENTAL is a premier academic journal published by W B SAUNDERS CO-ELSEVIER INC, with a distinguished history dating back to 1952. This journal serves as a vital repository of knowledge in the fields of Endocrinology, Diabetes, and Metabolism, consistently ranking in the top quartile (Q1) within these categories according to the latest metrics. With an impressive impact factor and recognized for its contributions to Biochemistry, Genetics, and Molecular Biology, it ranks #5 out of 128 in the Scopus database for Endocrinology and #11 out of 244 for Medicine related to Endocrinology, Diabetes, and Metabolism, placing it in the 95th and 96th percentiles, respectively. While the journal does not currently offer open access, it maintains rigorous peer review standards and publishes cutting-edge research that drives forward the understanding of metabolic diseases and clinical practices. By engaging with METABOLISM-CLINICAL AND EXPERIMENTAL, researchers, healthcare professionals, and students can explore groundbreaking advancements and pivotal findings that shape the future of metabolic health.

Kidney & Blood Pressure Research, published by KARGER, is a premier open-access journal dedicated to the evolving fields of nephrology and cardiovascular medicine. Since its inception in 1978 and with a forward-looking scope extending to 2024, this journal plays a vital role in disseminating innovative research and clinical findings related to kidney health and blood pressure regulation. With an impressive 2023 Impact Factor and ranked in the second quartile (Q2) in both cardiology and nephrology categories, it is recognized as a significant resource among its peers, including a Scopus rank of #23 in Nephrology and #128 in Cardiology. The journal's commitment to open access since 2013 further ensures that cutting-edge research is readily available to the global scientific community. Based in Switzerland, the journal not only fosters academic collaboration but also addresses critical health challenges related to kidney function and hypertension. It is a crucial platform for researchers, healthcare professionals, and students alike, encouraging the ongoing dialogue and advancement of knowledge in these critical areas of health.

HYPERTENSION RESEARCH, published by SpringerNature, serves as a premier platform in the field of Cardiology and Cardiovascular Medicine, Internal Medicine, and Physiology. Since its inception in 1992, the journal has built a substantial reputation, currently ranked in the second quartile (Q2) across several categories in 2023, reflecting its influence and high-quality contributions to medical research. With a focus on hypertension, the journal aims to disseminate vital research findings, clinical studies, and innovative treatment strategies to a diverse audience of researchers, healthcare professionals, and students, fostering knowledge exchange in the management of hypertensive conditions. Although it is not an Open Access journal, it offers comprehensive access to its extensive archive of valuable resources, ensuring that critical advancements in the understanding of hypertension are both accessible and impactful. HYPERTENSION RESEARCH is not only essential for those directly involved in cardiovascular and internal medicine practices but also for interdisciplinary scholars who are looking to explore the intersections of physiology and other biomedical fields in their work.

HYPERTENSION, published by Lippincott Williams & Wilkins, is a preeminent journal in the field of cardiovascular medicine, focusing on the latest research, therapies, and clinical practices related to hypertension and its associated disorders. With a distinguished Q1 ranking in Internal Medicine and a commendable Scopus rank of #12 out of 167 in its category, it occupies a vital position within the academic community, appealing to researchers, clinicians, and educators alike. The journal has been disseminating impactful findings since 1979 and continues to influence the discourse on hypertension through rigorous peer-reviewed articles, reviews, and studies designed to elevate understanding and treatment of this prevalent condition. HYPERTENSION remains an essential resource for professionals keen on advancing their knowledge in this critical area of medicine, fostering innovations that ultimately improve patient care.

BLOOD PRESSURE is a distinguished journal published by Taylor & Francis Ltd in the field of cardiology and internal medicine, with an ISSN of 0803-7051 and E-ISSN of 1651-1999. Since its inception in 1992, it has become a vital source of research and clinical information, dedicated to advancing our understanding of blood pressure-related health issues. With a notable categorization of Q3 in Cardiology and Cardiovascular Medicine and Q2 in Internal Medicine as of 2023, this journal exemplifies a commitment to evidence-based findings that impact clinical practice and patient care. The journal facilitates a platform for original research, reviews, and case studies, aiming to bridge the gap between researchers and practitioners. Although it does not currently offer open access, BLOOD PRESSURE remains an essential resource for professionals and students alike, striving to enhance health outcomes through dedication to innovative cardiovascular research.

Cardiovascular Diabetology is a prestigious open-access journal published by BMC, focusing on the intersecting fields of cardiology, endocrinology, diabetes, and internal medicine. Since its inception in 2002, this journal has established itself as a vital resource for researchers, clinicians, and academics dedicated to advancing knowledge in these areas. With an impressive impact factor reflected in its Q1 rankings for the year 2023 across its respective categories, including a ranking of 22nd in Cardiology and Cardiovascular Medicine and notably 15th in Internal Medicine, it positions itself at the forefront of scholarly communication. The journal encourages the dissemination and sharing of groundbreaking research, providing open access to foster engagement and collaboration among professionals globally. As it converges from 2002 to 2024, Cardiovascular Diabetology continues to be a pivotal platform for innovative studies, reviews, and critical insights that significantly impact clinical practices and medical education in the evolving landscape of cardiovascular health and diabetes management.